Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimodinduced murine psoriasis and impedes the transendothelial migration of mononuclear cells.
Mol Med Rep
; 22(1): 507-515, 2020 07.
Article
en En
| MEDLINE
| ID: mdl-32377714
ABSTRACT
During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, nonsteroidal and steroidal drugs, as well as antibodies to block tumor necrosis factorα, interleukin (IL)17A and IL12/IL23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits transendothelial migration in vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oligopéptidos
/
Psoriasis
/
Leucocitos Mononucleares
/
Células Endoteliales
/
Migración Transendotelial y Transepitelial
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Mol Med Rep
Año:
2020
Tipo del documento:
Article
País de afiliación:
México